The Mortality and Survival page discusses the fact that, particularly in studies concerning racial differences in cancer outcomes, researchers commonly refer to relative differences in survival and relative differences in mortality interchangeably, often stating they are analyzing one relative difference while in fact analyzing the other, but without recognizing that the two relative differences tend to change in opposite directions as overall survival rates change or that more survivable conditions tend to show larger relative differences in mortality but smaller relative differences in survival than less survivable conditions. Several of the tables on that page illustrate the pattern whereby the rarer an outcome the greater tends to be the relative difference in experiencing it and the smaller tends to be the relative difference in avoiding it. These include Table N1, which presents an example where localized cancer shows a smaller relative difference in survival but larger relative difference in mortality than regionalized cancer. Table 1 below present similar data on five-years survival/mortality for nine types of cancer according to three stages (local, regional, distant) based on Figure 4 of the American Cancer Society’s Cancer Facts and Figures for African Americans 2013-2014. The final column also shows the EES, for estimated effect size, which is a measure of disparity theoretically unaffected by the prevalence of an outcome (as discussed on the Solutions subpage of Measuring Health Disparities page).
Table 1. White and black five-year survival rates by type of cancer and stage with ratio of white survival rate to black survival rate and black mortality rate to white mortality rate and estimate effect size (from American Cancer Society data) [refb4127a2]
Type
Stage
WSR
BSR
WBSuvrRatio
BWMortRatio
EES
Female Breast
Localized
99.00%
93.00%
1.06
7.00
0.86
Female Breast
Regional
85.00%
73.00%
1.16
1.80
0.43
Female Breast
Distant
25.00%
15.00%
1.67
1.13
0.37
Colorectum
Localized
90.00%
86.00%
1.05
1.40
0.21
Colorectum
Regional
70.00%
64.00%
1.09
1.20
0.18
Colorectum
Distant
12.00%
9.00%
1.33
1.03
0.17
Esophagus
Localized
40.00%
20.00%
2.00
1.33
0.59
Esophagus
Regional
21.00%
14.00%
1.50
1.09
0.28
Esophagus
Distant
3.00%
3.00%
1.00
1.00
Lung & Bronchus
Localized
53.00%
44.00%
1.20
1.19
0.24
Lung & Bronchus
Regional
25.00%
23.00%
1.09
1.03
0.07
Lung & Bronchus
Distant
4.00%
4.00%
1.00
1.00
Oral Cav & Pharnyx
Localized
83.00%
75.00%
1.11
1.47
0.29
Oral Cav & Pharnyx
Regional
60.00%
38.00%
1.58
1.55
0.58
Oral Cav & Pharnyx
Distant
35.00%
24.00%
1.46
1.17
0.33
Prostate
Localized
100.00%
100.00%
1.00
Prostate
Regional
100.00%
100.00%
1.00
Prostate
Distant
28.00%
27.00%
1.04
1.01
0.03
Urinary Bladder
Localized
70.00%
62.00%
1.13
1.27
0.23
Urinary Bladder
Regional
33.00%
29.00%
1.14
1.06
0.13
Urinary Bladder
Distant
6.00%
6.00%
1.00
1.00
Uterine Cervix
Localized
92.00%
84.00%
1.10
2.00
0.42
Uterine Cervix
Regional
58.00%
51.00%
1.14
1.17
0.19
Uterine Cervix
Distant
17.00%
11.00%
1.55
1.07
0.28
Uterine Corpus
Localized
96.00%
85.00%
1.13
3.75
0.72
Uterine Corpus
Regional
70.00%
44.00%
1.59
1.87
0.7
Uterine Corpus
Distant
18.00%
9.00%
2.00
1.11
0.43
There are only minor departures from the pattern whereby as survival decreases from stage to stage, relative differences in mortality decrease while relative differences in survival increase.
One observes a more striking pattern when the focus is limited to the stages with the highest and lowest survival and the common situation where the white survival rate is greater than the black survival rates for both stages, as shown in Table 2.
Table 2. White and black five-year survival rates by type of cancer and stage with ratio of white survival rate to black survival rate and black mortality rate to white mortality rate and estimated effect size (limited to local and distant and situations where white survival is greater than black survival for both stages) (from American Cancer Society data) [refb4127a4]